|Articles|September 10, 2020
- Pharmaceutical Executive-09-01-2020
- Volume 40
- Issue 9
Pharmaceutical Executive, September 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 6 years ago
Our Launch-Time Menualmost 6 years ago
Drug Launch: Winning the Evidence Battlealmost 6 years ago
COVID Causes Pharma Marketers to Watch TValmost 6 years ago
Succession Plan: Skyrizialmost 6 years ago
New Standards for First-to-Launch Playersalmost 6 years ago
(O)mega Opportunity: Vascepaalmost 6 years ago
Educational Mission: Oxbrytaalmost 6 years ago
First in Class: Spravatoalmost 6 years ago
One Time for Lifetime: Zolgensmaalmost 6 years ago
Biopharma Capital Markets Sizzle in 2020Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
2
FDA Approves Daraxonrasib as First-in-Class Targeted Therapy for Metastatic Pancreatic Cancer
3
The Retailization of Medicare Advantage: What Costco’s Entry Means for Pharma
4
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
5